All News
ILD in Juvenile Dermatomyositis: Moving Toward Better Outcomes
Juvenile dermatomyositis (JDM) is typically recognized for its striking skin rashes, vasculopathy, and muscle inflammation. Less visible, but equally significant, is lung involvement.
Read Article
"It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has." – William Osler
Dr. John Cush RheumNow ( View Tweet)
Review of GLP-1 agonist use in rheumatology - with benefits beyond DM, obesity, improved survival, reduced major cardiovascular and renal events. Anti-inflammatory & chondroprotective effx shown benefit in knee OA & pain. GLP-1RAs do not prevent gout attacks. More research https://t.co/8zh18mlYDh
Dr. John Cush RheumNow ( View Tweet)
Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/4MX2IiDC2X
Dr. John Cush RheumNow ( View Tweet)
Activity Trackers Can Predict RA Flares
People with rheumatoid arthritis (RA) who experienced disease flares often showed changes in heart rate and physical activity captured by popular wearable devices 4 weeks before they became clinically apparent, a small study indicated. https://t.co/LjE0LkJTrB
Dr. John Cush RheumNow ( View Tweet)
NY Times on Osteoporosis in Men
The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening...
Read more: https://t.co/SzNtuPllY6 https://t.co/13EcEfv4ab
Dr. John Cush RheumNow ( View Tweet)
HMGCR Abs is assoc w/ necrotizing myopathy. Review of 78 pts w/ HMGCR IMNM. 31 had overlap w/ higher MMT-score, less muscle weakness, more ILD, arthralgia, wt loss & rash. 12 had musc. dystrophy like dz w/ earlier onset, longer duration, less myalgia & extramuscular Sxs https://t.co/RpzZI0zI7E
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Still's Dz (240 articles, 95 sJIA, 134 AOSD, 23,136 pts); sJIA Dx by ILAR in 78% & AOSD used Yamaguchi criteria 98%. While clinical and lab findings were matched betw AOSD & sJIA, there was variability in MAS , outocmes & trajectory. Standarization needed
Dr. John Cush RheumNow ( View Tweet)
RheumNow is LIVE from #ACR25 Oct 24–29.
KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed. https://t.co/pPwJNOyEFU
Dr. John Cush RheumNow ( View Tweet)
Associations in Rheumatology (10.3.2025)
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.
https://t.co/pnLoquR4By https://t.co/PKJuxMGrZy
Dr. John Cush RheumNow ( View Tweet)
German survey of 124 AOSD pts - Dz duration 7 yrs (Dx delay 2 yrs), 2/3 on biologics, 84% responding, 81% inactive by CRP. MDs report 35% of pts Sx-free. More Patients report Persistent Sxs LBP (39.5%), fatigue/weakness (39%), & joint inflammation (27%). https://t.co/2FGUPrhB8H
Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT Cannabis sativa DKJ127 (VER-1) in 820 chronic low back pain (cLBP) pts. Primary endpt at wk 12 showed pain reduction of −1.9 NRS VER-01 vs −0.6 PBO (P < 0.001). Pain further decreased to −2.9 w/ 6 mos OL Rx. VER-1 was well tolerated. No addiction https://t.co/IeCV8tU2WR
Dr. John Cush RheumNow ( View Tweet)
Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/nbdZfBDukE
Dr. John Cush RheumNow ( View Tweet)
Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older https://t.co/GHjCgqHaJC
Dr. John Cush RheumNow ( View Tweet)
What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
https://t.co/ThU4pq27MU https://t.co/AOa5PALJst
Links:
Dr. John Cush RheumNow ( View Tweet)
🆕 ILD (Part III): clinical practice focus 🔬 Diagnostic challenges 🧑⚕️ Case-based learning 📈 Evidence & outcomes 🌍 Global perspectives ⬇️ Download & learn more: https://t.co/WhpVzAfPDD Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/4CL9mX9D6Y
Dr. John Cush RheumNow ( View Tweet)
There is no consensus on flare definition in PSA. Review of 12 #PsA studies shows flare prevalence ranged 7% to 10%, w/ incidence was 22–23%. Over 12 mos, current patient-reported flare = 10%, physician-reported flare = 7% https://t.co/2LKlnaMSyv https://t.co/0TYXiZGsSc
Dr. John Cush RheumNow ( View Tweet)
Small 38 pt. RCT found that 16-wks of Mediterranean diet signif improved psoriasis PASI scores. Intervention grp had better PASI change at week 16 (−3.4 vs 0), PASI 75, and reducted hemoglobin A1c. Diet as adjunctive Rx in PsO!! https://t.co/oJnaAA8LMm https://t.co/AXxI8FWQqU
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 137 pts w/ Usual interstitial pneumonia (UIP) w/ myositis Abs testing. 11% MSA+. & more like to have autoimmune Dz, +ANA, +RF. MSA negativity predicted by these 4: neg RF, ANA <1:320, no hypergammaglobulinemia, no Raynaud's - specificity 100%, sensitivity https://t.co/JAca1fpwZT
Dr. John Cush RheumNow ( View Tweet)
Detection, Monitoring & Management of Autoimmune ILD
The American Journal of Managed Care has reviewed the approach to patients with ILD; a significant cause of morbidity and mortality in those with SARDs, including RA, SSc, and IIM.
https://t.co/xtRfLNyZA6 https://t.co/S9JFlMd9CN
Dr. John Cush RheumNow ( View Tweet)
